Gilead collects 5th priority review voucher as public advocacy group urged the company to relinquish it

Gilead recently collected its 5th priority review voucher, this time for its megablockbuster Covid-19 drug remdesivir, which brought in $1.5 billion last quarter.

Many have questioned and critiqued the need for such lucrative vouchers, which can be used to speed another drug application by four months or sold for more than $100 million, particularly in instances where the products that are qualifying generate tens of billions annually.